78886-53-0 Usage
Uses
Used in Pharmaceutical Research:
4-AMinoisoquinolin-1(2H)-one is used as a pharmaceutical intermediate for the development of new drugs, particularly in the field of medicinal chemistry. Its unique structure and potential biological activities make it a valuable compound for designing and synthesizing novel therapeutic agents.
Used in Biochemistry:
In the field of biochemistry, 4-AMinoisoquinolin-1(2H)-one serves as a fluorescent probe for the detection of metal ions in biological systems. Its ability to bind and fluoresce in the presence of specific metal ions allows researchers to study metal ion interactions and their roles in biological processes.
Used in Anticancer Research:
4-AMinoisoquinolin-1(2H)-one has been investigated for its potential role as an anticancer agent. Its biological activities and interactions with cellular targets make it a promising candidate for further research and development in cancer therapy.
Used in Organic Synthesis:
4-AMinoisoquinolin-1(2H)-one is also utilized in organic synthesis for the preparation of various chemical entities and pharmaceuticals. Its versatility and reactivity in chemical reactions contribute to the advancement of synthetic chemistry and the creation of new molecules with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 78886-53-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,8,8 and 6 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 78886-53:
(7*7)+(6*8)+(5*8)+(4*8)+(3*6)+(2*5)+(1*3)=200
200 % 10 = 0
So 78886-53-0 is a valid CAS Registry Number.
78886-53-0Relevant academic research and scientific papers
CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]
-
Page/Page column 102, (2014/01/07)
The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
